L2 DIAGNOSTICS, LLC

Company Information
Address BOX 8175
NEW HAVEN, CT, 06530-0175


Information

DUNS: 142406110

# of Employees: N/A


Ownership Information

HUBZone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. A Rapid, Low-Cost Point of Care Diagnostic for detection of Zika virus RNA

    Amount: $225,000.00

    ABSTRACT Zika virus ZIKV has rapidly emerged and spread through South and Central America the Caribbean and Puerto Rico since its last outbreak in Micronesia in Transmitted by the mosquito A ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  2. Validation of a Diagnostic Test for Borrelia miyamotoi

    Amount: $299,905.00

    ABSTRACT Borrelia miyamotoi is a tick transmitted spirochete recently shown to cause infection and disease in the United States Europe and Asia A member of the relapsing fever group of Borrelia thi ...

    STTRPhase I2017Department of Health and Human Services National Institutes of Health
  3. Novel diagnostics for autoimmunity from checkpoint inhibitor immune therapy

    Amount: $299,754.00

    Checkpoint inhibitor CPI therapy has transformed treatment of solid tumors Clinical responses in the range of with prolonged survival have been reported for tumors such as malignant melan ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  4. Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma

    Amount: $298,959.00

    DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However ...

    STTRPhase I2016Department of Health and Human Services
  5. Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection

    Amount: $300,000.00

    DESCRIPTION provided by applicant The goal of this STTR is to identify novel small molecule compounds targeting the nitrogen respiration pathway of Pseudomonas aeruginosa This pathway is crucial t ...

    STTRPhase I2016Department of Health and Human Services
  6. Allosteric MIF Inhibitors for Rheumatoid Arthritis Therapy

    Amount: $1,475,498.00

    Abstract The long term product goal of this project is a small molecule rheumatoid arthritis RA therapeutic which acts by reducing the inflammatory response triggered by the pro inflammatory cytokin ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  7. IGF OT IGF Topic Phase I SBIR Predictive Biomarkers of Adverse Reactions to Prostate Cancer Radiotherapy

    Amount: $271,237.00

    Not Available

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  8. Therapeutic Inhibition of MIF in Type 1 Diabetes

    Amount: $297,302.00

    DESCRIPTION provided by applicant The long term product goal of this project is a small molecule therapeutic to prevent or treat Type diabetes T D Our objective is to reduce the inflammatory r ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  9. Targeted Inactivation of the CCR5 HIV Coreceptor with Peptide Nucleic Acids

    Amount: $250,298.00

    DESCRIPTION (provided by applicant): Over 34 million people are currently living with HIV/AIDS. Combination antiviral therapies have significantly reduced the morbidity and mortality of the disease; h ...

    SBIRPhase I2014Department of Health and Human Services
  10. Sterculic Acid Analogs to Inhibit Macular Degeneration

    Amount: $224,700.00

    ABSTRACT The long-term product goal of this project is a small molecule therapeutic for choroidal neovascularization (CNV, the hallmark of wet age-related macular degradation), an abnormal growth o ...

    SBIRPhase I2014Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government